2026-11-03

Daily 340B Morning Briefing | November 3, 2026

Recent 340B developments place access to discounts, control of program savings and data demands at the center of the debate. Reps. Doris Matsui and Tracey Mann introduced the PROTECT 340B Act on Oct. 29 to prohibit PBM and insurer discrimination against covered entities and contract pharmacies. In Kentucky, the University of Kentucky and Ashland Hospital Corporation sued CVS Health and affiliates on Oct. 27, alleging diversion of more than $41 million in 340B savings. Five Massachusetts hospitals sued Eli Lilly the same day, alleging Lilly unlawfully withheld discounts after they refused to provide patient claims data. Missouri Attorney General Catherine Hanaway’s Oct. 26 cease-and-desist letter separately gave Lilly until Nov. 26 to end its claims-data requirement for hospital discounts. Meanwhile, HRSA’s Oct. 25 pilot page specifies rebates equal to WAC minus the dispensing-date ceiling price and lists Jan. 1, 2027 implementation for AbbVie’s three drugs. Manufacturers and PhRMA have moved to intervene in the rebate litigation, adding another challenge over how 340B discounts will be administered.

EXECUTIVE SUMMARY
01
PROTECT 340B Act returns to Congress.
Reps. Doris Matsui and Tracey Mann introduced legislation Oct. 29 to prohibit PBM and insurer discrimination against covered entities and contract pharmacies.

02
Kentucky health system alleges CVS diverted more than $41 million.
The University of Kentucky and Ashland Hospital Corporation sued CVS Health and affiliates Oct. 27 over alleged diversion of 340B savings.

03
Five Massachusetts hospitals challenge Lilly’s data demands.
The hospitals sued Oct. 27, alleging Lilly unlawfully withheld 340B discounts after they refused to provide patient claims data.

04
Missouri gives Lilly a Nov. 26 deadline.
Attorney General Catherine Hanaway’s Oct. 26 cease-and-desist letter demanded an end to Lilly’s claims-data requirement for hospital discounts.

Source: STAT

05
HRSA specifies rebate calculations and eligible drugs.
Its Oct. 25 pilot page states rebates equal WAC minus the dispensing-date ceiling price and lists Jan. 1, 2027 implementation for AbbVie’s three drugs.

Source: HRSA

06
Drugmakers and PhRMA seek to defend the rebate pilot.
Manufacturers filed a motion to intervene Oct. 14 in American Hospital Association v. Kennedy; PhRMA filed its motion Oct. 15.

07
AHA requests changes to SUSTAIN 340B legislation.
AHA’s Oct. 27 comments supported upfront discounts, contract pharmacy protections and a neutral clearinghouse, but requested revisions to several provisions.

08
ASPE links reimbursement policy to concerns about 340B incentives.
Its Oct. 8 report cited a proposed ASP minus 33.4% reimbursement rate and estimated inflation-adjusted payments rose $3.6 billion during 2021-2023.

Source: HHS ASPE

09
Part D pharmacy reimbursement input is due Nov. 23.
Frier Levitt attorney Adino Barbarito told AJMC that responses to CMS’s request for information on PBM pharmacy reimbursement terms are due Nov. 23.

EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. For covered entities, the developments put the value and administration of 340B discounts in focus: the Kentucky and Massachusetts suits allege harm to savings or discounts, while Missouri has demanded an end to Lilly’s claims-data requirement. The PROTECT 340B Act would address discrimination by PBMs and insurers against covered entities and contract pharmacies, and AHA has supported upfront discounts, contract pharmacy protections and a neutral clearinghouse in SUSTAIN 340B while requesting revisions to several provisions. HRSA’s rebate pilot sets out a separate calculation and implementation date, and manufacturers and PhRMA are seeking to intervene in litigation over the pilot. Covered entities therefore face overlapping legislative, legal and administrative disputes over discount access, data requirements and rebate mechanics.
Emerging risks.

  • Becker’s Oct. 26 pilot account describes full-price upfront purchases for 21 drugs under approved plans from 10 manufacturers.
  • The Massachusetts plaintiffs allege Lilly cut off discounts after they refused patient claims-data demands; the complaint does not establish those allegations.
  • Hanaway said University of Missouri Health Care agreed to provide claims data but still did not receive Lilly discounts.
  • ASPE’s Oct. 8 report cites a proposed ASP minus 33.4% payment rate, not a final reimbursement policy.
  • Cabin Creek Health Systems told the Register-Herald that it uses 340B discounts to provide income-based prescription prices and write-offs for uninsured patients.
Emerging opportunities.

  • Review the PROTECT 340B Act’s proposed restrictions on lower reimbursement, additional fees and exclusion of contract pharmacies from networks.
  • Assess the SUSTAIN provisions AHA supported Oct. 27, including upfront discounts, contract pharmacy access and a neutral data clearinghouse.
  • Use HRSA’s published unit-level rebate formula to test calculations against the ceiling price on each dispensing date.
  • Consider input on Part D pharmacy reimbursement terms before the Nov. 23 response deadline reported by AJMC.
Key actions for providers.

  • Map affected purchases against HRSA’s active IPAY 2026/2027 selected-drug scope, which applies regardless of payer or indication.
  • Prepare purchase and rebate reconciliation for AbbVie’s Imbruvica, Linzess and Vraylar before their listed Jan. 1, 2027 implementation date.
  • Track Lilly’s response to Missouri’s Nov. 26 demand separately from the Massachusetts hospitals’ Oct. 27 lawsuit.
  • Track the Oct. 14 manufacturer motion to intervene and PhRMA’s Oct. 15 motion without treating either request as court approval.
  • Review PBM reimbursement and fee terms against the practices addressed in the Oct. 29 PROTECT 340B Act proposal.
TOP STORIES
Kentucky plaintiffs allege CVS entities diverted more than $41 million
Becker’s Hospital Review · October 30, 2026
  • The University of Kentucky and Ashland Hospital Corporation sued CVS Health and affiliates Oct. 27.
  • The complaint alleges defendants diverted more than $41 million in 340B savings from the health system.
  • Defendants include CVS Health, CaremarkPCS Health, Caremark d/b/a CVS Specialty and WellPartner.
  • Ashland Hospital Corporation operates UK King’s Daughters Medical Center.
  • The plaintiffs filed in the U.S. District Court for the Eastern District of Kentucky.
Massachusetts hospitals sue Lilly over withheld discounts
Becker’s Hospital Review · October 27, 2026
  • Five Massachusetts hospitals sued Eli Lilly Oct. 27 in the U.S. District Court for the District of Massachusetts.
  • The plaintiffs allege Lilly unlawfully cut off discounts after they refused to provide patient claims data.
  • The complaint alleges violations of Massachusetts’ consumer protection law and unjust enrichment.
  • Plaintiffs include Massachusetts General Hospital, Brigham and Women’s Hospital, North Shore Medical Center, and two UMass Memorial hospitals.
Manufacturers and PhRMA seek intervention in rebate litigation
Becker’s Hospital Review · October 16, 2026
  • AbbVie, Pharmacyclics, Bristol Myers Squibb and Boehringer Ingelheim filed a motion to intervene Oct. 14.
  • PhRMA filed its own motion Oct. 15 in American Hospital Association v. Kennedy.
  • The case is before the U.S. District Court for the District of Maine.
  • The manufacturers seek to defend HRSA-approved rebate plans for their drugs.
  • The hospital industry’s lawsuit seeks to block HRSA’s revised 340B Rebate Model Pilot Program.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
PROTECT 340B Act would restrict PBM and insurer discrimination
Becker’s Hospital Review · November 2, 2026
  • Reps. Doris Matsui, D-Calif., and Tracey Mann, R-Kan., introduced the bipartisan PROTECT 340B Act Oct. 29.
  • The bill would prohibit lower reimbursement rates for 340B drugs and additional fees on covered entities and their contract pharmacies.
  • The proposal would prohibit exclusion of 340B contract pharmacies from networks and other discriminatory conditions based on program participation.
  • The Association of American Medical Colleges and other hospital groups endorsed the bill.
AJMC reports Nov. 23 deadline for Part D reimbursement input
The American Journal of Managed Care · October 30, 2026
  • Frier Levitt attorney Adino Barbarito said CMS requested information on pharmacy reimbursement terms in PBM contracts, with responses due Nov. 23.
  • Barbarito expects a proposed rule around April 2027 before pharmacy contract standards take effect for plan years beginning Jan. 1, 2029.
  • The Consolidated Appropriations Act of 2026 became law Feb. 3, 2026.
  • AJMC reports most PBM provisions take effect for plan years beginning Aug. 3, 2028, or Jan. 1, 2029 for calendar-year plans.
AHA backs SUSTAIN provisions but requests revisions
American Hospital Association · October 28, 2026
  • AHA submitted comments on the SUSTAIN 340B Act Oct. 27.
  • The bill would establish a national, neutral third-party clearinghouse and a durable patient definition.
  • AHA supported provisions to preserve upfront discounts, protect contract pharmacy use and prohibit health plan and PBM discrimination.
  • AHA asked sponsors to reconsider several provisions to avoid reducing access to medications or essential healthcare services.
HRSA lists rebate formula and AbbVie implementation date
HRSA · October 25, 2026
  • HRSA lists Jan. 1, 2027 implementation for AbbVie’s Imbruvica, Linzess and Vraylar.
  • Rebates equal WAC minus the 340B ceiling price on the dispensing date.
  • HRSA specifies unit-level payment rather than accumulation of a full package size.
  • The pilot applies only to active IPAY 2026/2027 selected drugs during each drug’s price applicability period.
  • Eligible selected drugs fall within the pilot regardless of payer or indication.
ASPE report questions incentives and cites proposed reimbursement cut
HHS ASPE · October 8, 2026
  • ASPE’s Oct. 8 report argues that 340B margins may encourage consolidation and behavior that raises healthcare costs.
  • ASPE estimated inflation-adjusted payments for non-exempt providers’ 340B drugs rose from $7.1 billion in 2021 to $10.7 billion in 2023.
  • The report cites CMS’s proposed ASP minus 33.4% reimbursement rate as an effort to reflect reported acquisition costs.
  • ASPE reported $81 billion in 2024 340B drug sales, including $64.1 billion in disproportionate share hospital purchases.
340B PROGRAM DEVELOPMENTS
Lilly’s January data-policy expansion included in-house dispensing
Becker’s Hospital Review · October 12, 2026
  • Becker’s Oct. 12 account describes Lilly’s January expansion of its existing contract pharmacy data requirement to in-house dispensing.
  • Lilly cited the need to identify duplicate discounts under the IRA.
  • The company gave covered entities until Feb. 1 to comply.
STATE DEVELOPMENTS
Kansas: 340B committee recommends new legislation and transparency provisions
Kansas Hospital Association · Oct. 21, 2026
  • The Special Committee on the 340B Drug Pricing Program met October 19-20 for interim hearings on the program’s funding and its impact on Kansas providers.
  • The committee recommended that lawmakers consider a bill similar to SB 284 with transparency provisions, and examine other states’ laws on passing 340B discounts to patients.
LITIGATION & ENFORCEMENT WATCH
Court Matter Date
U.S. District Court for the Eastern District of Kentucky The University of Kentucky and Ashland Hospital Corporation sued CVS Health and affiliates Oct. 27; plaintiffs allege diversion of more than $41 million in 340B savings. [source] 2026-10-30
U.S. District Court for the District of Massachusetts Five Massachusetts hospitals sued Eli Lilly Oct. 27; plaintiffs allege unlawful denial of discounts after they refused patient claims-data demands. [source] 2026-10-27
U.S. District Court for the District of Maine American Hospital Association v. Kennedy; manufacturers filed a motion to intervene Oct. 14, followed by PhRMA’s Oct. 15 motion. [source] 2026-10-16
MANUFACTURER WATCH
Manufacturer Action Date
Eli Lilly Expanded its contract pharmacy claims-data requirement in January to include in-house dispensing, with a Feb. 1 compliance deadline. [source] 2026-10-12
AbbVie HRSA lists Jan. 1, 2027 rebate implementation for Imbruvica, Linzess and Vraylar. [source] 2026-10-25
Amgen Has an HRSA-approved rebate plan in the revised 340B pilot. [source] 2026-10-26
Astellas Has an HRSA-approved rebate plan in the revised 340B pilot. [source] 2026-10-26
AstraZeneca Has an HRSA-approved rebate plan in the revised 340B pilot. [source] 2026-10-26
Bristol Myers Squibb Has an HRSA-approved rebate plan in the revised 340B pilot. [source] 2026-10-26
Boehringer Ingelheim Has an HRSA-approved rebate plan in the revised 340B pilot. [source] 2026-10-26
GSK Has an HRSA-approved rebate plan in the revised 340B pilot. [source] 2026-10-26
Merck Has an HRSA-approved rebate plan in the revised 340B pilot. [source] 2026-10-26
Pfizer Has an HRSA-approved rebate plan in the revised 340B pilot. [source] 2026-10-26
Teva Has an HRSA-approved rebate plan in the revised 340B pilot. [source] 2026-10-26
SOCIAL MEDIA & STAKEHOLDER SENTIMENT

The review screened dated official association and manufacturer material, policy and newsletter commentary, LinkedIn, and Reddit for 340B reactions published from August 5 through November 3, 2026, and retained direct-source items while noting when posts were advocacy or anonymous discussion.

September 2026 340B Office Hour: Rebate Model Pilot Program
National Association of Community Health Centers · September 14, 2026
  • Main theme: NACHC’s office-hour slides described new J&J claims-submission rules and a planned limit of one contract pharmacy or site for 340B-priced J&J drugs, while noting that state exemptions were unclear.
  • Stakeholder sentiment: NACHC presenters Nick Widmyer and Sam Campbell gave a concerned operational update; the slides specifically flag uncertainty about which states would be exempt.
  • Potential implications: Health centers had to assess claims reporting and pharmacy access under the schedule that placed the single-site limit on November 3, 2026.
  • Credibility: NACHC’s own presentation is a direct source for its member update; it is an advocacy and operational briefing, not an independent assessment.
Is anyone else’s hospital pharmacy struggling this much??
Reddit, r/pharmacy · August 7, 2026
  • Main theme: In a hospital-pharmacy staffing discussion, commenters offered opposing views of 340B: one called it a revenue option for pharmacy departments, while another accused hospitals of “fleec[ing]” the program.
  • Stakeholder sentiment: Anonymous pharmacy commenters are divided. u/WaveyandLazy called 340B “one example” of a revenue option; u/LongApricot said hospitals “fleece the 340B program.”
  • Potential implications: The exchange shows that 340B can prompt disagreement among pharmacy workers about departmental funding and whether savings reach patients.
  • Credibility: Direct Reddit comments, but anonymous and anecdotal; the 340B discussion is a small part of a broader staffing thread.
WHAT TO WATCH NEXT
  • Nov. 23: Monitor the response deadline for CMS’s Part D pharmacy reimbursement request for information, as reported by attorney Adino Barbarito. [source]
  • Nov. 26: Watch Lilly’s response to Missouri Attorney General Catherine Hanaway’s demand to end its hospital claims-data policy. [source]
  • Jan. 1, 2027: Track the listed rebate implementation date for AbbVie’s Imbruvica, Linzess and Vraylar. [source]
  • Monitor court action on the Oct. 14 manufacturer motion to intervene and PhRMA’s Oct. 15 motion in American Hospital Association v. Kennedy. [source]
  • Track congressional action on the PROTECT 340B Act introduced Oct. 29; its PBM and insurer restrictions remain proposed legislation. [source]
  • Watch revisions to SUSTAIN 340B provisions after AHA’s Oct. 27 request for changes to protect patient access. [source]
End of briefing.

This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.

© 2026 MedMatrix Rx. All rights reserved.

Post information

Schedule Your 340B Assessment

Connecting healthcare organizations to their full potential through compliant 340B optimization.